Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.
R Donghi, … , G Della Porta, M A Pierotti
R Donghi, … , G Della Porta, M A Pierotti
Published April 1, 1993
Citation Information: J Clin Invest. 1993;91(4):1753-1760. https://doi.org/10.1172/JCI116385.
View: Text | PDF
Research Article Article has an altmetric score of 13

Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.

  • Text
  • PDF
Abstract

The p53 gene was analyzed in tumor specimens obtained from 52 patients with various types of carcinoma of the thyroid gland by a combined molecular and immunocytochemical approach. The histologic types included 37 well-differentiated papillary and follicular carcinomas, 8 poorly differentiated, and 7 undifferentiated carcinomas. The p53 gene was shown to be unaffected in all differentiated tumors by single-strand conformation polymorphism analysis. However, in two out of eight (25%) of poorly differentiated carcinomas and five out of seven (71%) undifferentiated carcinomas, p53 mutations were identified and subsequently characterized by DNA sequencing. One undifferentiated carcinoma displayed two areas with varying degrees of differentiation. The comparative analysis of the p53 gene, in both the more and the less differentiated area of this tumor, clearly showed that the p53 mutation was confined to the latter component of the tumor specimen. These results indicate that mutations of the p53 gene are associated with the most aggressive histologic types of thyroid tumors, such as the undifferentiated carcinoma and, to a certain extent, the poorly differentiated carcinoma, and that the alterations of this gene represent a late genetic event in human thyroid carcinogenesis.

Authors

R Donghi, A Longoni, S Pilotti, P Michieli, G Della Porta, M A Pierotti

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1980 Total
Citations: 2 2 3 2 6 7 6 5 13 11 6 12 17 4 14 7 7 11 13 7 8 9 9 11 10 13 8 12 8 14 6 9 1 273
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2013 (17)

Title and authors Publication Year
Tumour suppressor role of the CL2/DRO1/CCDC80 gene in thyroid carcinogenesis.
Angelo Ferraro, Filippo Schepis, vincenza leone, Antonella Federico, Eleonora Borbone, Pierlorenzo Pallante, Maria Teresa Berlingieri, Gennaro Chiapetta, Mario Monaco, Claudio Arra, Giuseppe Palma, Dario Palmieri, Giancarlo Troncone, Lorenzo Chiariotti, Massimo Santoro, Alfredo Fusco
2013
Molecular pathogenesis and mechanisms of thyroid cancer
M Xing
Nature Reviews Cancer 2013
Genetics and epigenetics of sporadic thyroid cancer
D Vu-Phan, RJ Koenig
Molecular and Cellular Endocrinology 2013
Deregulation of microRNA expression in thyroid neoplasias
P Pallante, S Battista, GM Pierantoni, A Fusco
Nature Reviews Endocrinology 2013
Progress in molecular-based management of differentiated thyroid cancer
M Xing, BR Haugen, M Schlumberger
The Lancet 2013
eLS
YC Chang, YH Yu, LM Chuang
Encyclopedia of Life Sciences 2013
Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature
R Granata, L Locati, L Licitra
Current Opinion in Oncology 2013
Genetic mutations, molecular markers and future directions in research
KN Patel
Oral Oncology 2013
Recent progress of genome study for anaplastic thyroid cancer
J Lee, JA Hwang, EK Lee
Genomics & Informatics 2013
Essential genes in thyroid cancers: focus on fascin
H Samimi, MZ Dizaji, M Ghadami, AS Fazeli, P Khashayar, M Soleimani, B Larijani, V Haghpanah
Journal of Diabetes & Metabolic Disorders 2013
The sodium/iodide symporter NIS is a transcriptional target of the p53-family members in liver cancer cells
F Guerrieri, S Piconese, C Lacoste, V Schinzari, B Testoni, Y Valogne, S Gerbal-Chaloin, D Samuel, C Bréchot, J Faivre, M Levrero
Cell Death and Disease 2013
p53 antibody: is it an indicator of dedifferentiated thyroid cancer?
Z Hasbek, B Turgut, T Erselcan
Annals of Nuclear Medicine 2013
Targeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer
MN Nikiforova, AI Wald, S Roy, MB Durso, YE Nikiforov
The Journal of clinical endocrinology and metabolism 2013
Prognostic value of epidermal growth factor receptor, p53 and galectin-3 expression in papillary thyroid carcinoma
YM Lee, JB Lee
J INT MED RES 2013
Molecular Pathology and Diagnostics of Cancer
D Coppola
2013
Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review
A Guerra, VD Crescenzo, A Garzi, M Cinelli, C Carlomagno, M Tonacchera, P Zeppa, M Vitale
BMC surgery 2013
Nodular goiter with amyloid deposition in an elderly patient: fine-needle cytology diagnosis and review of the literature
VD Crescenzo, A Garzi, F Petruzziello, M Cinelli, L Catalano, P Zeppa, M Vitale
BMC surgery 2013

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 1 news outlets
Referenced in 2 patents
Referenced in 1 clinical guideline sources
55 readers on Mendeley
See more details